We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

38 hedge funds and large institutions have $14.1M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

31% more call options, than puts

Call options by funds: $63K | Put options by funds: $48K

23% more funds holding

Funds holding: 3138 (+7)

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

25% less capital invested

Capital invested by funds: $18.7M → $14.1M (-$4.67M)

Holders
38
Holders Change
+7
Holders Change %
+22.58%
% of All Funds
0.87%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
8
Reduced
7
Closed
3
Calls
$63K
Puts
$48K
Net Calls
+$15K
Net Calls Change
-$244K

FRTX Hedge Fund Activity: Q1 2018 in Review

38 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q1 2018, worth a combined $14.1M — down 25% from $18.7M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new FRTX positions and 3 closed out — a net gain of 7 holders — while 8 added to existing stakes and 7 trimmed.

The largest buyer was Armistice Capital, adding an estimated $473K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.24M sold.

  • 38 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q1 2018, up from 31 in Q4 2017.
  • Funds reported $14.1M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q1 2018, down 25% quarter-over-quarter.
  • 10 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q1 2018 and 3 closed out, a net change of +7 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q1 2018 was Armistice Capital, an estimated $473K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q1 2018 was Stonepine Capital Management, an estimated $1.24M sold.

Based on aggregated 13F filings for Q1 2018.